Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)

Background: Management of Non-Small Cell Lung Cancer (NSCLC) patients with oligoprogression remains controversial. There is limited data to support the strategy of Stereotactic Ablative Radiotherapy (SABR) targeting the oligoprogressive disease in combination with ongoing systemic treatment. We aim...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Houda Bahig, Marion Tonneau, Normand Blais, Philip Wong, Edith Filion, Marie-Pierre Campeau, Toni Vu, Afnan Al-Saleh, Mustapha Tehfé, Marie Florescu, David Roberge, Laura Masucci, Corentin Richard, Cynthia Menard, Bertrand Routy
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2022-03-01
Schriftenreihe:	Clinical and Translational Radiation Oncology
Schlagworte:	Stereotactic body radiation therapy Non-Small Cell Lung Cancer Oligoprogression
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2405630821001075
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!